Connect with us

Cannabis

CYIOS Corp’s Wholly Owned Subsidiary Choice Wellness Officially Launches New Online Store for Its DR’s CHOICE CBD and “24” Hand Sanitizer Brands

Newsfile

Published

on

Aventura, Florida–(Newsfile Corp. – June 19, 2020) – CYIOS Corp (OTC Pink: CYIO), a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, is pleased to announce it has launched its new online-retail web platform at www.choicewellnessbrands.com. Concurrent with the launch is a social media and marketing campaign aimed at product awareness and driving traffic to the site. The Company will also be utilizing the Cicero Transact data base as part of its ongoing marketing plans.

Mr. O’Shea Chiarman of CYIOS Corp. commented, “We are very pleased to have launched our new online retail store and happy to report the expansion of our product offerings to include; DR’s CHOICE brand of CBD topicals and tinctures, 24 HAND SANITIZER, and other wellness products including KN-95 face masks, infrared non-contact hand held thermometer, and soon to be released Personal Protection Equipment including Level 1 Isolation Gowns, Full Face plastic shields for medical professionals and Doctors on the front line. The first run of our 24 HAND SANITIZER will be packaged in 2oz tubes at a FDA registered facility that will also be handling all of our fulfillment with anticipated shipping availability in 1-2 weeks. Sales have already commenced with some larger orders and we are confident our new products, new online store and product marketing efforts will generate strong interest from retail consumers and from various industries seeking better and more effective sanitizing solutions.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2020/06/cyios-corps-wholly-owned-subsidiary-choice-wellness-officially-launches-new-online-store-for-its-drs-choice-cbd-and-24-hand-sanitizer-brands.jpg?w=740&ssl=1

“24” Hand Sanitizer

To view an enhanced version of this graphic, please visit:
https://grassnews.net/wp-content/uploads/2020/06/cyios-corps-wholly-owned-subsidiary-choice-wellness-officially-launches-new-online-store-for-its-drs-choice-cbd-and-24-hand-sanitizer-brands.jpg

The Problem in a pandemic is that harmful germs are everywhere, and consumers need to be educated that alcohol-based sanitizer is not the best long-term solution. Alcohol-based sanitizer products provide a one-time kill and only last for 1-2 minutes per use or until hands have dried. Once dried, you have no further protection against harmful germs and re-contamination as you venture out in public, head to work, and/or conduct daily routine. Alcohol can be absorbed into skin and is toxic if ingested which is not good if you have children to protect. Alcohol sanitizer stings if there is any skin abrasion on hands and must be used over and over all day, every day to combat germs while out in public. Typical thick alcohol sanitizer gel takes longer to dry, dries out skin and changes your skin’s natural PH.

The Solution: 24 HAND SANITIZER kills 99.99% of germs, is alcohol-free and formulated & enhanced with Zetrisil®. Zetrisil® is a nano antimicrobial technology that creates a shield of protection on your hands and provides persistent long-lasting protection that helps prevent re-contamination of harmful germs that your hands may come into contact with from your daily routine, workplace and/or out in public. The fast acting, quick drying formula leaves hands soft and smooth, is safe for children and contains NO ALCOHOL = Non flammable, Non-toxic AND NO STING! Importantly, 24 is more economical than traditional alcohol-based products due to lower overall usage need per day and per month. AND, it’s MADE IN THE USA!

Mr. O’Shea went on to say, “Unlike alcohol based sanitizer, there is some unique science behind 24 HAND SANITIZER. The physical kill of germs is accomplished by the active ingredient Benzolkonium Chloride which is one of only three (and the only one that is non-alcohol) active ingredients allowed by the FDA for use in hand sanitizer. 24 HAND SANITIZER is formulated and enhanced with Zetrisil®. Zetrisil® is a proprietary nano-based silicone compound which effectively protects and/or “shields” the area that 24 HAND SANITIZER is applied to from bacterial contamination by way of a long-lasting, cationic-charged, anti-microbial nano-silicone coating. In other words, Zetrisil® creates a shield of protection on your hands and provides persistent activity that helps prevent re-contamination of harmful germs that your hands may come into contact with in between washings, while at work, and/or while out in public. As Governments, States and Cities continue to open, giving rise to new pandemic cases, we feel it’s important to offer a safer alternative to alcohol based sanitizers and to provide a hand sanitizing solution that can give people some confidence and a little peace of mind that their sanitizing regimen will do more than a one-time kill of germs, by way of providing an additional important benefit of long-lasting protection from re-contamination.”

CONTACT INFORMATION
info@choicewellnessbrands.com

Investors are encouraged to follow CYIOS using:
www.twitter.com/cyioscorp
www.linkedin.com/company/cyios-corporation-llc
www.facebook.com/cyioscorporation

About ChoiceWellness, Inc:

ChoiceWellness, Inc. is a health and wellness company that has brought to market the DR’s CHOICE line of products, as well as the “24” Brand Hand Sanitizer products. DR’s CHOICE was developed with a mission to offer Doctors and Medical Practitioners their own Professional Grade CBD BRAND with a suite of products they could stand behind and be confident to offer to their patients. Our customers can be assured that DR’s CHOICE CBD products have gone through the highest scrutiny of testing for purity, potency and quality. DR’s Choice products have been brought to market for Doctors and Medical Professionals seeking a better solution for patients suffering from pain, inflammation, anxiety or other persistent symptoms. For more information please visit www.choicewellnessbrands.com

About CYIOS Corporation:

CYIOS Corporation is a publicly traded company focused developing and marketing specialty branded products in the Health and Wellness markets, including the “DR’s CHOICE” and “24” brand of products. The team has in-depth knowledge of the health and wellness markets, financial services industry, medical and health services, and blockchain. The Company looks to develop, distribute, and license proprietary products as well as evaluate potential acquisition opportunities. Further, the Company continues to seek and evaluate attractive business opportunities and to leverage its resources and expertise to build a diversified, sustainable business model. For more information please visit www.cyioscorporation.com

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements.” Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” & other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered w/ these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2020/06/cyios-corps-wholly-owned-subsidiary-choice-wellness-officially-launches-new-online-store-for-its-drs-choice-cbd-and-24-hand-sanitizer-brands-1.jpg?w=740&ssl=1

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58209

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Emerald Health Therapeutics Announces Stock Option Grant

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – August 3, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five years. All stock options will vest 25% on the date of grant and 25% on the first three anniversaries of the date of grant. Emerald has also granted an aggregate of 175,000 restricted share units to certain employees. The restricted share units will vest one year from the grant date and convert into common shares of Emerald at a fair market value of $0.21 per common share. The stock options and restricted share units have been granted pursuant to Emerald’s Omnibus Incentive Plan which has been previously approved by Emerald’s shareholders and the TSX Venture.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and production excellence. Emerald’s three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Metro Vancouver, BC-based greenhouse operation (78,000 square feet) capable of producing organic-certified product; Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square feet); and Pure Sunfarms, its 41.3%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 M square feet). Its Emerald Naturals subsidiary has launched a new natural wellness product category with its non-cannabis endocannabinoid-supporting product line and is expanding distribution across Canada.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60965

Continue Reading

Cannabis

PAOG Outlines Strategic Next Steps and Corporate Housecleaning Agenda

Newsfile

Published

on

Sandusky, Ohio–(Newsfile Corp. – August 3, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today released a letter from CEO James C. DiPrima to update shareholders on strategic next steps in addition to reviewing corporate housecleaning agenda items. The letter is included in its entirety below:

Cannot view this image? Visit: https://i2.wp.com/grassnews.net/wp-content/uploads/2020/08/paog-outlines-strategic-next-steps-and-corporate-housecleaning-agenda.jpg?w=740&ssl=1
PAOG New Logo

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6729/60946_7bc5829b742ca8b9_001full.jpg

Dear Shareholder,

The last three weeks have been busy for PAOG. Much has been accomplished – a management takeover, and two acquisitions. Expect the momentum to continue. Key contracts moving the company’s acquired cannabis biopharmaceutical technology forward are coming soon.

PAOG anticipates entering into a Contract Research Organization (CRO) agreement as a first step toward initiating an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for its RespRx Chronic Obstructive Pulmonary Disease (COPD) treatment.

Based on positive results from an informal trial of RexpRX with 25 COVID-19 patients, PAOG also plans to make a Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.

At the same time that we are advancing our cannabis biopharmaceutical technology, we also have some general housekeeping to catch up on. PAOG is behind on its reports required to maintain “current information” status with OTC Markets. We also need to update our website and contact information. We expect to complete all promptly.

A new website is now available. The site is preliminary. Look for continuous updates. Please sign-up for our newsletter and we’ll let you know when to check back.

You can find our new website at www.paogroupinc.com.

Thank you for your interest in our mission to advance the future of medical cannabis technology.

Best Regards,
James C. DiPrima

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60946

Continue Reading

Cannabis

Spyder Cannabis Disclosure Update

Newsfile

Published

on

Vaughan, Ontario–(Newsfile Corp. – July 31, 2020) –  Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) provides an update to the filing of disclosure documents as a result of COVID-19:

Filing of Annual Disclosure Documents Due to COVID-19

In a press release dated June 25, 2020, the Company announced, among other things, that due to circumstances created by the COVID – 19 pandemic, it would not be filing its April 30, 2020 quarterly report and management discussion and analysis which was due June 29, 2020.

The Company reports that it has yet to file its April 30, 2020 quarterly report and management discussion and analysis to date.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: corporate@spydercannabis.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60930

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania